Kynam Capital Management Reports 8.77% Ownership Stake in Celldex Therapeutics, Inc. (CLDX)

Kynam Capital Management, LP, along with its general partner Kynam Capital Management GP, LLC and Managing Member Yue Tang, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Celldex Therapeutics, Inc. (CLDX). The filing reports an aggregate ownership of 5,840,567 shares of common stock, representing 8.77% of the company's outstanding shares. This reflects an increase in their position compared to previous disclosures where ownership was effectively zero. The reporting persons share voting and dispositive power over the reported shares. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. Kynam Capital Management is based in Princeton, New Jersey, and the shares are held for investment purposes. This amendment marks the third update for this specific reporting group regarding their interest in Celldex Therapeutics.